title: Biological therapies in moderate and severe psoriasis: perspectives and certainties.
abstract: An inflammatory, proliferative condition with chronic evolution and systemic response, psoriasis, is positioned today among the most common inflammatory skin diseases affecting the Caucasian population worldwide. With a significant incidence, psoriasis has been increasingly defined as a disease with a major impact on the patient's life and the society to which he/she belongs. This paper conducts an analysis of the currently available therapies for the treatment of moderate and severe psoriasis, therapies with biological agents obtained through sophisticated genetic engineering technologies. Recent research and the increasing interest in therapeutic methods as complete and efficient as possible make us optimistic and confident in the future.
authors: "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
authors: M M
authors: MM
authors: Constantin
authors: "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
authors: E
authors: E
authors: Poenaru
authors: "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
authors: T
authors: T
authors: Constantin
authors: Cisco Systems Romania.
authors: C
authors: C
authors: Poenaru
authors: "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
authors: V L
authors: VL
authors: Purcarea
authors: "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
authors: B R
authors: BR
authors: Mateescu
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D001691:Biological Therapy; D000068800:Etanercept / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology*; D000069549:Ustekinumab / Q000627:therapeutic use
chemical_list: D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept
keywords: anti-TNF; immunogenicity; psoriasis